{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"258","value":"211"},{"groupId":"OG001","spread":"502","value":"621"},{"groupId":"OG002","spread":"444","value":"731"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"88"}],"units":"Participants"}],"description":"The steady state concentration of blinatumomab was summarized as the observed concentrations collected at least 10 hours after the start of the IV infusion or dose step for cycle 1 and cycle 2, respectively. Serum concentrations of blinatumomab were measured using a validated bioassay. The lower limit of quantitation (LLOQ) = 50.0 pg/mL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants receiving 9 μg/day blinatumomab by continuous intravenous (CIV) infusion during Cycle 1.","id":"OG000","title":"Cycle 1: Blinatumomab 9 μg/Day"},{"description":"Participants receiving 28 μg/day blinatumomab by continuous intravenous (CIV) infusion during Cycle 1.","id":"OG001","title":"Cycle 1: Blinatumomab 28 μg/Day"},{"description":"Participants receiving 28 μg/day blinatumomab by continuous intravenous (CIV) infusion during Cycle 2.","id":"OG002","title":"Cycle 2: Blinatumomab 28 μg/Day"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic Data Set (PKS) defined as all patients who received any infusion of blinatumomab and had at least one PK sample collected unless significant protocol deviations affected the data analysis or if key dosing, dosing interruption or sampling information was missing.","reportingStatus":"POSTED","timeFrame":"Samples were taken before treatment start and on Days 3, 8, 10, 15, 22, and 29 after infusion start during Cycles 1 and 2.","title":"Serum Blinatumomab Concentration at Steady State","type":"SECONDARY","unitOfMeasure":"pg/mL"}